Study on Therapy of Non-invasive Prolactinoma

NCT ID: NCT03353025

Last Updated: 2017-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

394 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

the study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non-invasive prolactinomas were treated by transsphenoidal surgery or Dopamine agonist until now. However,this two type therapies were controversial. The study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prolactinoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

non-invasive prolactinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

transsphenoidal surgery treatment

Transsphenoidal surgery treat non-invasive prolactinoma by experienced neurosurgeon

Group Type EXPERIMENTAL

transsphenoidal surgery treatment

Intervention Type PROCEDURE

transsphenoidal surgery treatment

dopamine agonist treatment

Minimum effective dose of dopamine agonist, bromocriptine, treat non-invasive prolactinoma

Group Type EXPERIMENTAL

dopamine agonist treatment

Intervention Type DRUG

Minimum effective dose of dopamine agonist,bromocriptine,treat prolactinona

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

transsphenoidal surgery treatment

transsphenoidal surgery treatment

Intervention Type PROCEDURE

dopamine agonist treatment

Minimum effective dose of dopamine agonist,bromocriptine,treat prolactinona

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TSS DA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

non-invasive prolactionma

Exclusion Criteria

invasive prolactioma
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

First Affiliated Hospital, Sun Yat-Sen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hai-Jun Wang

director

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Haijun Wang, Dr.

Role: STUDY_CHAIR

First Affiliated Hospital, Sun Yat-Sen University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sun Yat-sen 5010 program

Guangzhou, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zongming Wang, Dr.

Role: CONTACT

Phone: 8613570903721

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Haijun Wang, doctor

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016008

Identifier Type: -

Identifier Source: org_study_id